GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Name: GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?
Start: 2021-05-27T00:00:00Z
End: 2021-05-27T00:00:00Z

May 27, 2021

Webinar

LSPN Connect

Finnegan partner Cora Holt will discuss the potential impact the GSK v Teva case will have on both brand and generic drug manufacturers. For more information, or to register, please see LSPN Connect’s website.

Related Insights

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Tags

Related Practices

Related Industries

Related Professionals

Related Insights